RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Corcept Therapeutics - Stock

Corcept Therapeutics ROCE 2024

Corcept Therapeutics ROCE

0.21

Ticker

CORT

ISIN

US2183521028

WKN

529882

In 2024, Corcept Therapeutics's return on capital employed (ROCE) was 0.21, a -5.65% increase from the 0.22 ROCE in the previous year.

Corcept Therapeutics Aktienanalyse

What does Corcept Therapeutics do?

Corcept Therapeutics Inc is a biopharmaceutical company specializing in the development of drugs for the treatment of metabolic, hormonal, and cancer-related diseases. The company was founded in 1998 by Dr. Joseph Belanoff, who still serves as the Chief Executive Officer. The history of Corcept Therapeutics is closely linked to the discovery of mifepristone, a drug that acts as an antagonist to cortisol receptors. In 2002, the company acquired the rights to mifepristone from Roussel Uclaf, a subsidiary of Hoechst AG, and developed it into the drug Korlym (mifepristone). Korlym was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of patients with endogenous Cushing's syndrome, a severe hormone disorder. The core business of Corcept Therapeutics is the research and development of drugs that affect the body's hormonal balance. In addition to Korlym, the company has also brought other innovative drugs to the market aimed at alleviating or even curing the symptoms of hormonal disorders. These drugs include relacorilant, which is currently undergoing Phase III studies for the treatment of patients with Cushing's syndrome. Another division of Corcept Therapeutics is the development of drugs for the treatment of cancer. The company has conducted several clinical trials to test the efficacy of its drug Korlym in treating certain types of cancer, including breast cancer, lung cancer, and prostate cancer. More recently, Corcept Therapeutics has also developed a new drug called Exicure, which focuses on the treatment of liver cancer. Overall, Corcept Therapeutics has built a wide portfolio of products and services targeting patients with different medical needs. The company has also formed partnerships with other companies and research institutes to support its research and development efforts and improve access to its products. The business model of Corcept Therapeutics is based on partnerships with physicians, hospitals, and clinics that utilize its products and services to help patients with metabolic, hormonal, and cancer-related diseases. The company also relies on close collaboration with the FDA and other regulatory agencies to ensure that its drugs meet the highest standards of safety and efficacy. Corcept Therapeutics is headquartered in Menlo Park, California, USA, and currently employs around 250 people. The company has experienced strong growth in recent years, both through the development of new products and the expansion of its business into global markets. In summary, Corcept Therapeutics Inc is a leading biopharmaceutical company specializing in the development of drugs for the treatment of hormone, metabolic, and cancer-related diseases. With its broad portfolio of innovative products and services, the company has made a significant contribution to improving the health and well-being of millions of people worldwide. Corcept Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Corcept Therapeutics's Return on Capital Employed (ROCE)

Corcept Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Corcept Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Corcept Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Corcept Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Corcept Therapeutics Stock

What is the ROCE (Return on Capital Employed) of Corcept Therapeutics this year?

The ROCE of Corcept Therapeutics is 0.21 undefined this year.

How has the ROCE (Return on Capital Employed) of Corcept Therapeutics developed compared to the previous year?

The ROCE of Corcept Therapeutics has increased by -5.65% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Corcept Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Corcept Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Corcept Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Corcept Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Corcept Therapeutics impact the company?

An increase in the ROCE of Corcept Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Corcept Therapeutics affect the company?

A decrease in ROCE of Corcept Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Corcept Therapeutics?

Some factors that can affect Corcept Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Corcept Therapeutics so important for investors?

The ROCE of Corcept Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Corcept Therapeutics take to improve the ROCE?

To improve the ROCE, Corcept Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Corcept Therapeutics pay?

Over the past 12 months, Corcept Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Corcept Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Corcept Therapeutics?

The current dividend yield of Corcept Therapeutics is .

When does Corcept Therapeutics pay dividends?

Corcept Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Corcept Therapeutics?

Corcept Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Corcept Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Corcept Therapeutics located?

Corcept Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Corcept Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Corcept Therapeutics from 6/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/21/2024.

When did Corcept Therapeutics pay the last dividend?

The last dividend was paid out on 6/21/2024.

What was the dividend of Corcept Therapeutics in the year 2023?

In the year 2023, Corcept Therapeutics distributed 0 USD as dividends.

In which currency does Corcept Therapeutics pay out the dividend?

The dividends of Corcept Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Corcept Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Corcept Therapeutics

Our stock analysis for Corcept Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Corcept Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.